Extramedullary plasmacytoma is an unusual manifestation in multiple myeloma (MM). It can present as a solitary bone lesion and/or soft-tissue mass. Plasmacytoma can be presented at any location, but it is more common in the head and neck, usually without systemic involvement. The presence of plasmacytoma in MM is a predictor of rapidly progressive disease. The value of fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (PET-FDG) is increasing, in the diagnosis, detection of occult lesions, and therapeutic monitoring. We describe a patient with rapidly-progressive, refractory, left pectoral muscle plasmacytoma and MM. A PET-FDG guided the therapy and allowed to identify the presence of disease relapse. A 69-year-old male was admitted to our hospital referred from another center with the diagnosis of diffuse large B cell lymphoma. The patient complained of chest pain and a left hemithorax mass that grew rapidly for 1 month. Physical examination identified a large, solid, and painful mass at the left chest wall extending from the sternum to the axillary region, attached to deep planes.
A 69-year-old male was admitted to our hospital referred from another center with the diagnosis of diffuse large B cell lymphoma. The patient complained of chest pain and a left hemithorax mass that grew rapidly for 1 month. Physical examination identified a large, solid, and painful mass at the left chest wall extending from the sternum to the axillary region, attached to deep planes.
A whole-body computed tomography (CT) (images not available) showed a presternal mass that extended into the left pectoral muscles and subcutaneous tissue associated with mediastinal and left axillary lymph nodes. A fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/CT (PET/CT) (PET-FDG) was requested for staging [ Figure 1a and b]. PET-FDG showed a giant soft-tissue mass that involved the left chest wall, extending down to the sternum and ribs (maximum standardized uptake value [SUVmax] 14.17), associated with multiple hypermetabolic mediastinal and axillary lymph nodes. In addition, hypermetabolic bone lesions in the spine, ribs, pelvis, and extremities were also observed.
In view of the PET/CT imaging findings, a core needle biopsy of the left pectoral muscle mass and bone marrow aspiration was done, revealing infiltration by plasmatic cells (52%). Immunohistochemical staining of the tumor cells was positive for CD138, CD38, and CD56 and negative for PAX-5, EMA, CD20, and CD30 [ Figure 2 ].
Laboratory findings revealed decreased serum albumin 3.2 g/dl (normal range, 3.5-5.2 g/dl) and hemoglobin 9.7 g/dl (normal range, 13.5-17.5 g/dl) and increased lactic acid dehydrogenase 229 U/L (normal range, 105-215 U/L), beta 2 microglobulin 5.7 mg/L (normal range, 1.2-2.5 mg/L), serum IgG 6.3 g/dl (normal range, 0.7-1.5 g/dl) and kappa monoclonal protein 5.3 g/dl. Despite local radiotherapy and Len/Dex and VBMCP/ VBAD chemotherapy regimens, the chest wall mass progressed with clinical worsening and severe infectious complications. The patient died 7 months after the last PET-FDG. Autopsy revealed cutaneous tumor dissemination in the thoracic and abdominal walls, visceral plasmacytomas, medullary aplasia, and signs of multiple organ failure.
The abnormal production of clonal plasma cells in the bone marrow causes as a result a MM, which represents about 10% of hematological cancers.
[1] The classical clinical characteristics include hypercalcemia, renal failure, anemia, and bone lesions. However, other forms of plasma cell neoplasia can be present, and signs and symptoms may be unlike that include plasma cell leukemia, bone solitary plasmacytoma, extramedullary plasmacytoma, and MM with extramedullary involvement. [2] Extramedullary involvement is an uncommon presentation in MM, with an incidence of 2.2%-13% at the time of diagnosis. [2, 3] Nevertheless, the evidence shows that the extramedullary MM is a factor of rapidly progressive disease and poor prognostic. The development of different laboratory techniques as gene rearrangement and FISH has provided valuable predictive information about progression of MM to aggressive disease. In our case, the presence of cytogenetic abnormalities with 1q21 gain was an indicator of worse course of disease, lower response rate to treatments, and opposite predictor of progression-free survival.
The role of PET-FDG in the evaluation of MM is increasing. It represents a relevant procedure for the diagnosis, showing greater sensitivity (80%-100%) than conventional radiological imaging. [4] In addition, PET-CT provides information about the presence of extramedullary disease, allowing the detection of lesions clinically not suspected. PET-FDG plays a role for the evaluation of the therapeutic response, the assessment of patients with minimal residual disease, and the diagnosis of early tumor relapse, especially in patients who are eligible to receive autologous stem-cell transplantation. [5] Its potential role as a predictor of progression of solitary extramedullary plasmacytoma to MM is under debate. Recently, Albano et al. have reported that avid PET-FDG plasmacytoma showing elevated SUV seemed to be correlated with a higher risk of transformation in MM. [6] The case presented here shows the usefulness of PET-FDG for the diagnosis of medullary and extramedullary disease, the assessment of metabolic response to therapy, and the detection of early relapse that causes a change in the therapeutic approach. The morphofunctional assessment of the plasma cell disease plays a significant role as a predictor of progression, as in our case with fatal course.
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